(0.23%) 5 111.88 points
(0.18%) 38 310 points
(0.27%) 15 971 points
(-1.01%) $83.00
(4.99%) $2.02
(0.09%) $2 349.40
(0.16%) $27.58
(4.18%) $960.65
(-0.17%) $0.933
(-0.27%) $10.99
(-0.45%) $0.797
(1.74%) $93.48
0.02% $ 31.24
@ $31.23
Wydano: 8 vas. 2024 @ 16:30
Zwrot: 0.02%
Poprzedni sygnał: vas. 7 - 22:55
Poprzedni sygnał:
Zwrot: 5.67 %
Live Chart Being Loaded With Signals
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm...
Stats | |
---|---|
Dzisiejszy wolumen | 19.31M |
Średni wolumen | 8.29M |
Kapitalizacja rynkowa | 8.73B |
EPS | $0 ( 2024-04-26 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -111.55 |
ATR14 | $0.306 (0.98%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-12 | Mitchell Dean J | Sell | 103 000 | Common Stock |
2024-02-12 | Mitchell Dean J | Sell | 13 090 | Restricted Stock Unit |
2024-02-12 | Mitchell Dean J | Sell | 142 667 | Deferred Share Unit |
2024-02-12 | Mitchell Dean J | Sell | 10 000 | Stock Option (Right to Buy) |
2024-02-12 | Mitchell Dean J | Sell | 10 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 8 781 240 |
Wolumen Korelacja
ImmunoGen Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
HOL | 0.945 |
IRBT | 0.93 |
SLNG | 0.929 |
RTPY | 0.927 |
KBSF | 0.926 |
LGMK | 0.92 |
RPID | 0.919 |
FIBK | 0.917 |
GBCI | 0.917 |
LYEL | 0.917 |
10 Najbardziej negatywne korelacje | |
---|---|
AEAE | -0.941 |
ENTF | -0.941 |
CCTS | -0.941 |
HORI | -0.939 |
GHIX | -0.938 |
FIAC | -0.938 |
XPAX | -0.938 |
NECB | -0.936 |
ADAL | -0.935 |
ACAB | -0.935 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ImmunoGen Inc Korelacja - Waluta/Towar
ImmunoGen Inc Finanse
Annual | 2022 |
Przychody: | $108.78M |
Zysk brutto: | $108.61M (99.84 %) |
EPS: | $-0.880 |
FY | 2022 |
Przychody: | $108.78M |
Zysk brutto: | $108.61M (99.84 %) |
EPS: | $-0.880 |
FY | 2022 |
Przychody: | $108.78M |
Zysk brutto: | $108.61M (99.84 %) |
EPS: | $-0.880 |
FY | 2020 |
Przychody: | $132.30M |
Zysk brutto: | $17.71M (13.38 %) |
EPS: | $-0.250 |
Financial Reports:
No articles found.
ImmunoGen Inc
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej